US4882148A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Crack prevention and improved thrombogenicity of implanted prostheses by sulfonation
Assignee: Corvita Corp
•
Filing: 1987-06-18
•
Granted: 1989-11-21
•
Expires: 2007-06-18
Abstract
Abstract Implantable devices for medical use are provided which have been subjected to treatment with a crack preventative/antithrombogenic agent in the form of a sulfate. This treatment substantially prevents surface cracking or fissuring of the subcutaneous implantation as well as preventing thrombus formation along the blood contacting surfaces of the treated material.
Inventors
- 👤 Leonard Pinchuk
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 12:19
CPC Classifications
C; C08; C08J; C08J7/00; C08J7/12; C08J7/14; A; A61; A61L; A61L27/00; A61L27/14; A61L27/18; A61L33/00; A61L33/0076; A61L33/0082
Claims Analysis
Total Claims: 33
Claim 1
Independent Claim
161 words
A treatment method for substantially preventing in vivo cracking of biocompatible surfaces of implanted devices for medical use, consisting essentially of: providing a shaped substrate of an implantable medical device having a biocompatible polymeric surface that is susceptible to cracking when subjected to subcutaneous implantation under in vivo conditions for substantial time periods, such in vivo conditions including those that promote crack-forming biodegradation of said biocompatible polymeric surface; applying a crack preventive composition to said biocompatible polymeric surface, said crack preventive composition including a sulfonating agent, said sulfonating agent is selected from the group consisting of fuming sulfuric acid, concentrated sulfuric acid, sulfur trioxide vapors, and blends thereof with an alcohol or a blend of alcohols; reacting said sulfonating agent with said biocompatible polymeric surface in order to substantially prevent in vivo cracking of said surface without requiring any additional treatment of said surface; and said providing step includes selecting said substrate to contain a polymeric structure which contains aromatic moieties.
Claim 2
Dependent Claim
161 words
A treatment method for substantially preventing in vivo cracking of biocompatible surfaces of implanted devices for medical use, consisting essentially of: providing a shaped substrate of an implantable medical device having a biocompatible polymeric surface that is susceptible to cracking when subjected to subcutaneous implantation under in vivo conditions for substantial time periods, such in vivo conditions including those that promote crack-forming biodegradation of said biocompatible polymeric surface; applying a crack preventive composition to said biocompatible polymeric surface, said crack preventive composition including a sulfonating agent, said sulfonating agent is selected from the group consisting of fuming sulfuric acid, concentrated sulfuric acid, sulfur trioxide vapors, and blends thereof with an alcohol or a blend of alcohols; reacting said sulfonating agent with said biocompatible polymeric surface in order to substantially prevent in vivo cracking of said surface without requiring any additional treatment of said surface; and said providing step includes selecting said substrate to contain a polymeric structure which contains aromatic moieties.
Claim 3
Dependent Claim
28 words
The treatment method of claim 1 wherein said biocompatible polymeric surface is selected from the group consisting of aromatic polyurethanes, polyester terephthalates, polystyrenes, polysulfones and aromatic silicon rubbers.
Claim 4
Dependent Claim
22 words
The treatment method of claim 1 wherein said biocompatible polymeric surface is constructed of a unitary surface area of said biocompatible polymer.
Claim 5
Dependent Claim
22 words
The treatment method according to claim 1 wherein the crack preventive composition will not dissolve substantial portions of said biocompatible polymeric surface.
Claim 6
Dependent Claim
29 words
The treatment method according to claim 1 wherein the crack preventive composition is the product obtained by the addition of fuming sulfuric acid to one or more primary alcohols.
Claim 7
Dependent Claim
21 words
The treatment method of claim 1 wherein the crack preventive composition is made by the addition of sulfuric acid to ethanol.
Claim 8
Dependent Claim
27 words
The treatment method of claim 1 wherein the crack preventive composition is made by the addition of sulfuric acid to ethanol, said ethanol being blended with methanol.
Claim 9
Dependent Claim
21 words
The treatment method of claim 1 wherein the crack preventive composition is made by the addition of sulfuric acid to methanol.
Claim 10
Dependent Claim
22 words
The treatment method of claim 1 wherein said biocompatible polymeric surface is constructed of one or more strands of said biocompatible polymer.
Claim 11
Dependent Claim
15 words
The treatment method of claim 1 wherein said biocompatible polymeric surface is an aromatic polyurethane.
Claim 12
Dependent Claim
26 words
The treatment method of claim 1, wherein said in vivo conditions promote thrombus formation, and the device thus treated remains patent under such in vivo conditions.
Claim 13
Dependent Claim
136 words
A treatment method for substantially preventing in vivo thrombosis of biocompatible surfaces of synthetic vascular grafts, consisting essentially of: providing a shaped substrate of an implantable medical device having a biocompatible polymeric surface that is susceptible to thrombus formation when contacted with blood under in vivo conditions for substantial time periods, said in vivo conditions including those that promote thrombosis of said biocompatible polymeric surface; applying an antitrombogenic composition to said biocompatible polymeric surface, said antitrombogenic composition being made by the addition of a sulfur trioxide source to a primary alcohol; reacting said antitrombogenic composition with said biocompatible polymeric surface in order to substantially prevent in vivo thrombosis on said surface without requiring any additional treatment of said surface; and said providing step includes selecting said substrate to contain a polymeric structure which contains aromatic moieties.
Claim 14
Dependent Claim
136 words
A treatment method for substantially preventing in vivo thrombosis of biocompatible surfaces of synthetic vascular grafts, consisting essentially of: providing a shaped substrate of an implantable medical device having a biocompatible polymeric surface that is susceptible to thrombus formation when contacted with blood under in vivo conditions for substantial time periods, said in vivo conditions including those that promote thrombosis of said biocompatible polymeric surface; applying an antitrombogenic composition to said biocompatible polymeric surface, said antitrombogenic composition being made by the addition of a sulfur trioxide source to a primary alcohol; reacting said antitrombogenic composition with said biocompatible polymeric surface in order to substantially prevent in vivo thrombosis on said surface without requiring any additional treatment of said surface; and said providing step includes selecting said substrate to contain a polymeric structure which contains aromatic moieties.
Claim 15
Dependent Claim
30 words
The treatment method of claim 12, wherein said biocompatible surface is an aromatic polymer selected from the group consisting of aromatic polyurethanes, polyester terephthalates, polystyrenes, polysulfones and aromatic silicone rubbers.
Claim 16
Dependent Claim
14 words
The treatment method of claim 12, wherein said biocompatible surface is an aromatic polyurethane.
Claim 17
Dependent Claim
24 words
The treatment method of claim 12, wherein the biocompatible surface includes one or more extruded fibers that are shaped by winding over a mandrel.
Claim 18
Dependent Claim
16 words
The treatment method of claim 12, wherein the primary alcohol in said antithrombogenic composition is ethanol.
Claim 19
Dependent Claim
19 words
The treatment method of claim 12 wherein the primary alcohol in said antithrombogenic composition is ethanol denatured with methanol.
Claim 20
Dependent Claim
16 words
The treatment method of claim 12 wherein the primary alcohol in said antithrombogenic composition is methanol.
Claim 21
Dependent Claim
30 words
The treatment method of claim 12, wherein said in vivo conditions include exposure of at least part of said biocompatible polymeric surface to blood to form blood clots or thrombus.
Claim 22
Dependent Claim
20 words
The treatment method of claim 12, wherein the antithrombogenic composition will not dissolve substantial portions of said biocompatible polymeric surface.
Claim 23
Dependent Claim
14 words
The treatment method of claim 12, wherein the sulfur trioxide source is sulfuric acid.
Claim 24
Dependent Claim
139 words
An implantable device for medical use under in vivo conditions, consisting essentially of: a shaped substrate of an implantable medical device having a biocompatible polymeric surface that is susceptible to biodegradation cracking when subjected to subcutaneous implantation under in vivo conditions for substantial periods of time; said biocompatible polymeric surface further being susceptible to clotting or thrombus formation when contacted with blood under in vivo conditions for substantial periods of time; a crack preventative/antithrombogenic agent applied to said substrate, said crack preventative/antithrombogenic agent including sulfur trioxide; and said biocompatible polymeric surface is resistant to cracking and to thrombus formation under in vivo conditions after said crack preventative/antitrombogenic agent is applied thereto and reacted therewith in order to substantially prevent in vivo cracking and in vivo thrombosis of said surface without requiring any additional treatment of said biocompatible polymeric surface.
Claim 25
Dependent Claim
139 words
An implantable device for medical use under in vivo conditions, consisting essentially of: a shaped substrate of an implantable medical device having a biocompatible polymeric surface that is susceptible to biodegradation cracking when subjected to subcutaneous implantation under in vivo conditions for substantial periods of time; said biocompatible polymeric surface further being susceptible to clotting or thrombus formation when contacted with blood under in vivo conditions for substantial periods of time; a crack preventative/antithrombogenic agent applied to said substrate, said crack preventative/antithrombogenic agent including sulfur trioxide; and said biocompatible polymeric surface is resistant to cracking and to thrombus formation under in vivo conditions after said crack preventative/antitrombogenic agent is applied thereto and reacted therewith in order to substantially prevent in vivo cracking and in vivo thrombosis of said surface without requiring any additional treatment of said biocompatible polymeric surface.
Claim 26
Dependent Claim
29 words
The implantable device according to claim 22, wherein said biocompatible polymeric surface is selected from of group consisting the aromatic polyurethanes, polyester terephthalates, polystyrenes, polysulfones, and aromatic silicone rubbers.
Claim 27
Dependent Claim
16 words
The implantable device according to claim 22, wherein said biocompatible polymeric surface is an aromatic polyurethane.
Claim 28
Dependent Claim
26 words
The implantable device according to claim 22, wherein said biocompatible polymeric surface includes one or more extruded fibers that are shaped by winding over a mandrel.
Claim 29
Dependent Claim
21 words
The implantable device according to claim 22, wherein said biocompatible polymeric surface includes one or more strands of said biocompatible polymer.
Claim 30
Dependent Claim
20 words
The implantable device according to claim 22, wherein said biocompatible polymeric surface is in the shape of a vascular graft.
Claim 31
Dependent Claim
24 words
The implantable device according to claim 22, wherein said crack preventative/antithrombogenic agent, prior to its application to said biocompatible polymeric surface, includes sulfuric acid.
Claim 32
Dependent Claim
33 words
The implantable device according to claim 22, wherein said crack preventative/antithrombogenic agent, prior to its application to said biocompatible polymeric surface, is made by the addition of sulfuric acid to a primary alcohol.
Claim 33
Dependent Claim
21 words
The implantable device according to claim 22, wherein said biocompatible polymeric surface is in the shape of a cardiac lead insulator.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-11-20 | 1993-05-22 | 1993-11-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-11-20 | 1997-05-22 | 1997-11-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-11-20 | 2001-05-22 | 2001-11-21 | $7700.00 | Window Closed / Lapsed |